Is Novavax Inc (NVAX) overvalued? · P/E 2.5, rev $196.2M
Novavax Inc (NVAX) is a biotechnology company listed on US.
This page asks whether Novavax Inc (NVAX) looks expensive on cached numbers — not a short thesis.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
NVAX currently screens at market cap $1.09B and trailing P/E 2.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NVAX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NVAX stock page for the full model, not this heading.
Not investment advice.